Dogwood Therapeutics, Inc. Stock-Based Compensation
Dogwood Therapeutics, Inc. (DWTX) reported Stock-Based Compensation of $992.62 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $543.20K, a 735.35% increase year-over-year.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $449.42K, a 432.02% increase year-over-year.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $157.86K, a 68.29% increase year-over-year.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $48.28K, a 48.80% decline year-over-year.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $355.64K, a 25.29% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $476.02K, a 23.22% decline from fiscal 2023.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $619.97K, a 6.40% increase from fiscal 2022.
- Dogwood Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $582.66K, a 80.46% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $543.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $992.62K 10-Q · filed 2026-08-14 | $1.15M derived: sum of 3 quarters · filed 2026-08-14 | $1.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $449.42K 10-Q · filed 2026-05-15 | $607.28K derived: sum of 2 quarters · filed 2026-05-15 | $655.56K derived: sum of 3 quarters · filed 2026-05-15 | $720.59K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $157.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $206.14K derived: sum of 2 quarters · filed 2026-03-18 | $271.17K derived: sum of 3 quarters · filed 2026-08-14 | $355.64K 10-K · filed 2026-03-18 |
| 2025-09-30 | $48.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $113.31K derived: sum of 2 quarters · filed 2026-08-14 | $197.78K 10-Q · filed 2025-11-07 | $291.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $65.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $149.50K 10-Q · filed 2026-08-14 | $243.30K derived: sum of 3 quarters · filed 2026-08-14 | $337.61K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $84.47K 10-Q · filed 2026-05-15 | $178.28K derived: sum of 2 quarters · filed 2026-05-15 | $272.58K derived: sum of 3 quarters · filed 2026-05-15 | $421.53K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $93.80K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $188.10K derived: sum of 2 quarters · filed 2026-03-18 | $337.05K derived: sum of 3 quarters · filed 2026-03-18 | $476.02K 10-K · filed 2026-03-18 |
| 2024-09-30 | $94.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $243.25K derived: sum of 2 quarters · filed 2025-11-07 | $382.22K 10-Q · filed 2025-11-07 | $530.52K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $148.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $287.92K 10-Q · filed 2025-08-13 | $436.22K derived: sum of 3 quarters · filed 2025-08-13 | $584.53K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $138.97K 10-Q · filed 2025-05-09 | $287.27K derived: sum of 2 quarters · filed 2025-05-09 | $435.58K derived: sum of 3 quarters · filed 2025-05-09 | $597.24K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $148.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $296.61K derived: sum of 2 quarters · filed 2025-03-31 | $458.27K derived: sum of 3 quarters · filed 2025-03-31 | $619.97K 10-K · filed 2025-03-31 |
| 2023-09-30 | $148.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $309.97K derived: sum of 2 quarters · filed 2024-11-08 | $471.67K 10-Q · filed 2024-11-08 | $621.20K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $161.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $323.36K 10-Q · filed 2024-08-09 | $472.89K derived: sum of 3 quarters · filed 2024-08-09 | $637.16K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $161.70K 10-Q · filed 2024-05-10 | $311.23K derived: sum of 2 quarters · filed 2024-05-10 | $475.49K derived: sum of 3 quarters · filed 2024-05-10 | $612.45K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $149.53K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | $313.80K derived: sum of 2 quarters · filed 2024-03-08 | $450.75K derived: sum of 3 quarters · filed 2024-03-08 | $582.66K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | $164.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $301.22K derived: sum of 2 quarters · filed 2023-11-13 | $433.13K 10-Q · filed 2023-11-13 | $565.03K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $136.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $268.86K 10-Q · filed 2023-08-11 | $400.77K derived: sum of 3 quarters · filed 2023-08-11 | $532.67K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $131.91K 10-Q · filed 2023-05-12 | $263.81K derived: sum of 2 quarters · filed 2023-05-12 | $395.72K derived: sum of 3 quarters · filed 2023-05-12 | $429.96K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $131.91K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $263.81K derived: sum of 2 quarters · filed 2023-03-14 | $298.06K derived: sum of 3 quarters · filed 2023-03-14 | $322.88K 10-K · filed 2023-03-14 |
| 2021-09-30 | $131.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $166.15K derived: sum of 2 quarters · filed 2022-11-14 | $190.97K 10-Q · filed 2022-11-14 | $5.62M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $34.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $59.07K 10-Q · filed 2022-08-12 | $5.49M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $24.82K 10-Q · filed 2022-05-13 | $5.45M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $7.43M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |